{"timestamp": "2026-01-17T20:12:16.934585", "question": "{\"CASE_CORE\":{\"ADJUVANT_TREATMENT\":{\"cycles_or_courses\":\"6 cycles\",\"given\":\"Yes\",\"regimens\":[\"多西+顺铂\",\"多西+卡铂\"]},\"BIOMARKERS\":{\"AFP\":\"1.04 ng/ml\",\"CA125\":\"651.00 U/ml\",\"CA15-3\":\"156.00 U/ml\",\"CA19-9\":\"23.40 U/ml\",\"CEA\":\"1.13 ng/ml\",\"HE4\":\"1210.00 pmol/L\",\"HER2\":\"Unknown\",\"MSI\":\"Unknown\",\"PDL1_CPS\":\"Unknown\",\"ROMA\":\"99.50% (premenopausal); 98.26% (postmenopausal)\",\"TMB\":\"Unknown\"},\"BRCA1\":\"Unknown\",\"BRCA2\":\"Unknown\",\"CURRENT_STATUS\":\"Ovarian cancer with multiple metastases (CT 2025-04-09)\",\"DIAGNOSIS\":{\"components\":[],\"histology\":\"Unknown\",\"laterality\":\"Unknown\",\"primary\":\"Ovarian cancer\",\"site\":\"Ovary\"},\"HRD\":\"Unknown\",\"INITIAL_TREATMENT\":\"Yes\",\"LINE_OF_THERAPY\":[{\"cycles\":\"6 cycles\",\"end_date\":\"2019-08\",\"intent\":\"Adjuvant\",\"line\":\"1L\",\"regimen\":\"多西+顺铂; 多西+卡铂\",\"start_date\":\"2019-03-26\"},{\"cycles\":\"3 cycles\",\"end_date\":\"Unknown\",\"intent\":\"Salvage\",\"line\":\"Unknown\",\"regimen\":\"多柔比星脂质体\",\"start_date\":\"2019-11\"},{\"cycles\":\"6 cycles\",\"end_date\":\"2022-06\",\"intent\":\"Salvage\",\"line\":\"Unknown\",\"regimen\":\"白紫+贝伐\",\"start_date\":\"2021-05\"},{\"cycles\":\"5 cycles\",\"end_date\":\"Unknown\",\"intent\":\"Salvage\",\"line\":\"Unknown\",\"regimen\":\"多柔比星\",\"start_date\":\"2022-07\"},{\"cycles\":\"Unknown\",\"end_date\":\"2024-09\",\"intent\":\"Salvage\",\"line\":\"Unknown\",\"regimen\":\"口服安罗+尼拉\",\"start_date\":\"2023-01\"},{\"cycles\":\"3 cycles\",\"end_date\":\"Unknown\",\"intent\":\"Palliative\",\"line\":\"Unknown\",\"regimen\":\"多柔比星+奈达铂\",\"start_date\":\"2024-09\"},{\"cycles\":\"1\",\"end_date\":\"Unknown\",\"intent\":\"Palliative\",\"line\":\"Unknown\",\"regimen\":\"联合免疫治疗\",\"start_date\":\"Unknown\"}],\"MAINTENANCE\":\"Yes\",\"MAINTENANCE_DETAIL\":{\"end_date\":\"2022-06\",\"given\":\"Yes\",\"regimens\":[\"贝伐维持\"],\"start_date\":\"Unknown\"},\"NEOADJUVANT\":\"No\",\"PFI_days\":\"Unknown\",\"PLATINUM_HISTORY\":[{\"PFI_days\":\"Unknown\",\"end_date\":\"2019-08\",\"evidence\":\"CA125 ~110 in 2019.10\",\"evidence_type\":\"Biochemical\",\"first_relapse_date\":\"2019-10\",\"line\":\"1L\",\"start_date\":\"2019-03-26\",\"status\":\"Unknown\"},{\"PFI_days\":\"Unknown\",\"end_date\":\"Unknown\",\"evidence\":\"CT 2025-04-09: ovarian cancer multiple metastases\",\"evidence_type\":\"Radiologic\",\"first_relapse_date\":\"2025-04-09\",\"line\":\"Unknown\",\"start_date\":\"2024-09\",\"status\":\"Unknown\"}],\"PLATINUM_PFI_CURRENT\":\"Unknown\",\"PLATINUM_STATUS\":\"Unknown\",\"PLATINUM_STATUS_CURRENT\":\"Unknown\",\"RELAPSE\":\"Yes\",\"RELAPSE_DATE\":{\"date\":\"2019-10\",\"evidence\":\"CA125 ~110 in 2019.10\",\"type\":\"Biochemical\"},\"STAGE\":{\"stage_basis\":\"Unknown\",\"stage_system\":\"Unknown\",\"stage_text\":\"Unknown\"},\"SURGERY_DONE\":{\"date\":\"2019-03-26\",\"performed\":\"Yes\",\"procedure\":\"Surgery at outside hospital; postoperative hyperthermic perfusion\"},\"VISIT_DATE\":\"2025-06-27\",\"first_relapse_date\":\"2019-10\",\"last_platinum_end_date\":\"Unknown\"},\"LAB_TRENDS\":{\"labs\":[{\"analyte\":\"CA125\",\"history\":[{\"date\":\"2019-10\",\"flag\":\"↑\",\"value\":\"≈110\"}],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"↑\",\"value\":\"651.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"HE4\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"↑\",\"value\":\"1210.00\"},\"reference_range\":\"Unknown\",\"unit\":\"pmol/L\"},{\"analyte\":\"CA15-3\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"↑\",\"value\":\"156.00\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"CA19-9\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"Unknown\",\"value\":\"23.40\"},\"reference_range\":\"Unknown\",\"unit\":\"U/ml\"},{\"analyte\":\"AFP\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"Unknown\",\"value\":\"1.04\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"},{\"analyte\":\"CEA\",\"history\":[],\"latest\":{\"date\":\"2025-06-25\",\"flag\":\"Unknown\",\"value\":\"1.13\"},\"reference_range\":\"Unknown\",\"unit\":\"ng/ml\"},{\"analyte\":\"ALP\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"↑\",\"value\":\"143.6\"},\"reference_range\":\"Unknown\",\"unit\":\"U/L\"},{\"analyte\":\"ALB\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"↓\",\"value\":\"39.5\"},\"reference_range\":\"Unknown\",\"unit\":\"g/l\"},{\"analyte\":\"Hb\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"↓\",\"value\":\"67\"},\"reference_range\":\"Unknown\",\"unit\":\"g/l\"},{\"analyte\":\"RBC\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"↓\",\"value\":\"2.41\"},\"reference_range\":\"Unknown\",\"unit\":\"*10^12/L\"},{\"analyte\":\"WBC\",\"history\":[],\"latest\":{\"date\":\"2025-06-24\",\"flag\":\"Unknown\",\"value\":\"7.8\"},\"reference_range\":\"Unknown\",\"unit\":\"*10^9/L\"}],\"milestones\":[{\"date\":\"2019-03-26\",\"description\":\"Initial surgery at outside hospital\",\"type\":\"Surgery\"},{\"date\":\"2019-03-26\",\"description\":\"Start adjuvant chemotherapy\",\"type\":\"ChemoStart\"},{\"date\":\"2019-10\",\"description\":\"Biochemical relapse with CA125 elevation\",\"type\":\"Relapse\"},{\"date\":\"2025-04-09\",\"description\":\"CT showed multiple metastases\",\"type\":\"Imaging\"}]},\"MED_ONC\":{\"current_regimen\":{\"cycle_info\":\"Unknown\",\"last_admin_date\":\"Unknown\",\"name\":\"Unknown\"},\"genetic_testing\":{\"germline\":[],\"somatic\":[]},\"monitoring_points\":[],\"planned_next_regimen\":\"Unknown\",\"prior_systemic_therapies\":[\"多西+顺铂\",\"多西+卡铂\",\"多柔比星脂质体\",\"白紫+贝伐\",\"多柔比星\",\"口服安罗+尼拉\",\"多柔比星+奈达铂\",\"联合免疫治疗\",\"贝伐维持\"]},\"NUC_MED\":{\"studies\":[]},\"PATHOLOGY\":{\"specimens\":[]},\"RADIOLOGY\":{\"next_imaging_plan\":{\"modality\":\"Unknown\",\"timing\":\"Unknown\"},\"studies\":[{\"anatomic_sites\":[\"Ovary\",\"Multiple metastases\"],\"date\":\"2025-04-09\",\"findings\":[\"Ovarian cancer with multiple metastases\"],\"impression\":\"Ovarian cancer with multiple metastases\",\"modality\":\"CT\",\"trend_vs_prior\":\"Unknown\"}]},\"TIMELINE\":{\"constraints\":{\"max_events\":30,\"min_events\":3,\"must_include\":[\"first diagnostic imaging or pathology confirmation (if available)\"],\"ordering_rules\":{\"prioritize_last_event\":true}},\"events\":[{\"date\":\"2019-03-26\",\"description\":\"Surgery at outside hospital; postoperative hyperthermic perfusion\",\"event_type\":\"Surgery\",\"key_result\":\"\",\"regimen_or_test\":\"\"},{\"date\":\"2019-08\",\"description\":\"Completed adjuvant chemotherapy; PR\",\"event_type\":\"Chemo\",\"key_result\":\"PR\",\"regimen_or_test\":\"多西+卡铂\"},{\"date\":\"2019-10\",\"description\":\"CA125 increased to ~110\",\"event_type\":\"Lab\",\"key_result\":\"≈110 U/ml\",\"regimen_or_test\":\"CA125\"},{\"date\":\"2019-11\",\"description\":\"Salvage chemotherapy with 多柔比星脂质体, stopped due to pandemic\",\"event_type\":\"Chemo\",\"key_result\":\"3 cycles, stopped\",\"regimen_or_test\":\"多柔比星脂质体\"},{\"date\":\"2021-05\",\"description\":\"Tumor recurrence treated with 白紫+贝伐\",\"event_type\":\"Relapse\",\"key_result\":\"6 cycles; bevacizumab maintenance\",\"regimen_or_test\":\"白紫+贝伐\"},{\"date\":\"2022-06\",\"description\":\"Bevacizumab maintenance until 2022.06\",\"event_type\":\"Other\",\"key_result\":\"\",\"regimen_or_test\":\"贝伐维持\"},{\"date\":\"2022-07\",\"description\":\"多柔比星 monotherapy\",\"event_type\":\"Chemo\",\"key_result\":\"5 cycles\",\"regimen_or_test\":\"多柔比星\"},{\"date\":\"2023-01\",\"description\":\"Oral therapy started\",\"event_type\":\"Chemo\",\"key_result\":\"\",\"regimen_or_test\":\"口服安罗+尼拉\"},{\"date\":\"2024-09\",\"description\":\"Surgery with intestinal stoma for bowel obstruction; stopped oral therapy\",\"event_type\":\"Surgery\",\"key_result\":\"\",\"regimen_or_test\":\"intestinal stoma\"},{\"date\":\"2024-09\",\"description\":\"Chemotherapy 多柔比星+奈达铂\",\"event_type\":\"Chemo\",\"key_result\":\"3 cycles\",\"regimen_or_test\":\"多柔比星+奈达铂\"},{\"date\":\"Unknown\",\"description\":\"联合免疫治疗 once, achieved SD\",\"event_type\":\"Immunotherapy\",\"key_result\":\"SD\",\"regimen_or_test\":\"联合免疫治疗\"},{\"date\":\"2025-04-09\",\"description\":\"External CT showed ovarian cancer multiple metastases\",\"event_type\":\"Imaging\",\"key_result\":\"multiple metastases\",\"regimen_or_test\":\"CT\"},{\"date\":\"2025-06-24\",\"description\":\"Biochemistry and CBC abnormalities\",\"event_type\":\"Lab\",\"key_result\":\"ALP 143.6↑; ALB 39.5↓; HGB 67 g/l↓; RBC 2.41↓\",\"regimen_or_test\":\"Biochemistry/CBC\"},{\"date\":\"2025-06-25\",\"description\":\"Tumor markers elevated\",\"event_type\":\"Lab\",\"key_result\":\"CA125 651.00↑; HE4 1210.00↑; CA15-3 156.00↑; CA19-9 23.40; ROMA 99.50%/98.26%\",\"regimen_or_test\":\"CA125/HE4/CA15-3/CA19-9/ROMA\"}]}}", "final_output": "Final Assessment:\nHeavily pretreated recurrent metastatic ovarian cancer with severe anemia and incomplete pathology/imaging/biomarker data; prognosis guarded and decisions must follow stabilization and clarified goals.\n\nCore Treatment Strategy:\n- Urgently correct severe anemia and optimize nutrition/organ function before any further anti-tumor treatment [@20250624|14501112; @20250624|14000385].  \n- After stabilization, reassess ECOG, symptoms, and patient preferences; prioritize symptom-led palliative/supportive care if performance status poor.  \n- Retrieve full primary pathology and any prior molecular reports; if absent, evaluate feasibility/value of new profiling (including BRCA/HRD).  \n- Obtain complete 2025-04-09 CT report (±PET/CT if justified) to define burden/complications and identify candidates for local palliation.  \n\nChange Triggers:\n- If performance status remains ≥3 or patient declines further therapy, shift fully to best supportive and hospice-oriented care.  \n- If performance status ≤2 and patient desires treatment, reconsider limited systemic options versus focused local interventions at repeat MDT review.", "initial_ops": {"chair": "- Heavily pretreated metastatic ovarian cancer with rising markers and anemia; current systemic regimen and performance status are unknown/need update.  \n- Prior extensive platinum, liposomal/standard anthracycline, anti-angiogenic, PARP, and immunotherapy exposure suggests limited further cytotoxic benefit; clarify platinum sensitivity.  \n- Immediate priority: correct severe anemia (Hgb 67 g/L) and assess symptoms, nutrition, renal/hepatic function, ECOG.  \n- Obtain histology subtype, BRCA1/2 and HRD status, and complete 2025 imaging reports to guide further systemic vs best supportive care.  \n- Discuss goals of care with patient/family now, aligning intensity of future treatment with prognosis and quality-of-life priorities.", "oncologist": "- Heavily pretreated metastatic ovarian cancer with progression after multiple cytotoxic, anti-angiogenic, oral targeted, and immunotherapy regimens; palliative intent.  \n\n- Current disease progression: multiple metastases on CT 2025-04-09 with markedly rising CA125/HE4/CA15-3 [@20250625|13601595].  \n\n- Profound anemia (Hb 67 g/L) with preserved liver enzymes and creatinine; requires cause assessment and correction before further systemic therapy [@20250624|14501112][@20250624|14000385].  \n\n- No germline/somatic mutations, MSI, TMB, or PD-L1 data available; comprehensive molecular profiling status and reports need updating.  \n\n- Missing details: exact histology/grade, staging, performance status, organ function (full labs), prior regimen toxicities, prior response durations, and sites/symptoms.", "radiologist": "- CT shows ovarian malignancy with multiple metastatic sites; precise organs, sizes, and counts not specified and need updated imaging report. [@IMAGING_STUDIES|2025-04-09]\n\n- Overall metastatic burden and distribution trend versus any earlier baseline are unknown; prior comparison imaging, if available, needs review. [@IMAGING_TRENDS|2025-04-09]\n\n- No documentation of complications such as obstruction, ascites, or organ compromise; targeted CT/PET report needed to assess. [unknown/needs update]\n\n- Lesion measurability for response assessment (target vs non-target lesions) cannot be determined; require full radiology report with measurements. [unknown/needs update]", "pathologist": "- Markedly elevated CA125 and HE4 with high ROMA suggest strong suspicion for epithelial ovarian malignancy; histologic confirmation absent. [@MOLECULAR|unknown]  \n- Normal AFP, CEA, CA19-9, CA15-3 reduce support for primary germ cell or GI-type tumor markers. [@MOLECULAR|unknown]  \n- No tissue diagnosis, histologic type, or grade available; surgical pathology or biopsy report urgently needed. [@PATHOLOGY_REPORTS|unknown]  \n- HER2, MSI, PD-L1 CPS, and TMB all unknown; these biomarkers require dedicated testing if clinically indicated. [@MOLECULAR|unknown]  \n- Germline and somatic mutation panels show no reported variants; confirm panel type, genes covered, and report date. [@MOLECULAR|unknown]", "nuclear": "- No PET/CT report available; current staging metabolic extent is unknown/needs update [@PET_CT|unknown].  \n- Prior imaging shows ovarian cancer with multiple metastases, but metabolic activity pattern is unknown/needs update [@IMAGING_CONTEXT|2025-04-09].  \n- Cannot assess PET impact on upstaging/downstaging or recurrence suspicion without a current PET report; acquisition status unknown/needs update.  \n- Need PET/CT date, acquisition protocol, FDG-avid lesion distribution, and SUV metrics to refine metastatic burden assessment.  \n- Request upload/verification of latest PET/CT report to determine any change in staging or recurrence suspicion."}, "merged_summary": "Key Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.", "final_round_ops": {"Round 1": {"chair": "- Prioritize stabilization: evaluate anemia cause, consider transfusion, repeat CBC/biochem, document ECOG, symptoms, nutrition, comorbidities [@20250624|14501112; @20250624|14000385].  \n- Retrieve and review original pathology, including histologic subtype, grade, and any prior molecular testing; order germline/somatic profiling if absent.  \n- Obtain full 2025-04-09 CT report and any subsequent imaging; assess disease distribution, complications, and trend vs prior (currently unknown).  \n- Reconstruct detailed systemic treatment history (agents, dates, responses, toxicities, PFI) to clarify platinum status and realistic systemic options.  \n- After stabilization and data completion, hold MDT plus goals-of-care meeting to weigh further systemic therapy versus best supportive/palliative care.", "oncologist": "- Correct severe anemia urgently (transfusion and work-up), then document ECOG, symptom burden, nutrition, and comorbidities before any new regimen [@20250624|14501112].  \n\n- Obtain and review full 2025-04-09 CT report (organs involved, complications, comparison) and any PET/CT to reassess disease burden (currently missing).  \n\n- Retrieve original pathology to confirm epithelial subtype/grade and review any prior molecular testing; if absent, consider comprehensive profiling (currently unknown).  \n\n- Reconstruct detailed prior systemic treatment history, including responses and toxicities, to clarify platinum sensitivity and realistic benefit of further therapy (missing).  \n\n- After stabilization and data completion, re-discuss at MDT and with patient/family to choose between limited further systemic therapy versus best supportive care.", "radiologist": "- Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison) remains missing; must be retrieved/uploaded before MDT. [@IMAGING_STUDIES|2025-04-09]\n\n- PET/CT since 2025-04-09 is unknown; confirm if performed and obtain report/images to define metabolic burden and complications. [unknown/needs update]\n\n- Without full imaging, current disease extent, obstruction risk, or other complications cannot be adequately assessed for further systemic vs supportive care decisions. [@IMAGING_STUDIES|2025-04-09]\n\n- Once prior imaging is available, perform structured radiologic staging and measurability assessment to support objective response evaluation if therapy pursued. [unknown/needs update]", "pathologist": "- Retrieve and review original ovarian cancer pathology: histologic subtype, grade, stage, and biomarker profile are completely unknown/needs update.  \n- Obtain details of any prior molecular testing (BRCA1/2, HRD, MSI, TMB, PD-L1, HER2); currently unknown/needs update.  \n- Confirm disease origin as ovarian versus alternative primary once pathology is available; present clarification at next MDT.  \n- Once tissue and molecular data are complete, update pathology summary focusing on features relevant to further systemic options (no regimens suggested).  \n- Ensure all key pathology and molecular reports are uploaded and correctly dated to avoid future discrepancies in MDT decisions.", "nuclear": "- No PET/CT available; current metabolic disease distribution and recurrence pattern remain unknown/needs update [@PET_CT|unknown].  \n- Full CT 2025-04-09 report is still missing; without it, we cannot correlate anatomic and potential metabolic burden [@IMAGING_CONTEXT|2025-04-09].  \n- If PET/CT is performed, key goals: clarify extra-abdominal spread, occult nodal disease, and complications not fully characterized on CT.  \n- PET would meaningfully change staging only if it reveals unsuspected distant metastases or non-malignant explanations for some CT lesions.  \n- For suspected recurrence/progression, PET could reclassify equivocal CT findings, influencing decisions about local versus purely systemic/supportive approaches."}, "Round 2": {"chair": "- Correct severe anemia urgently, including transfusion consideration; reassess ECOG, symptoms, nutrition, and organ function afterward [@20250624|14501112; @20250624|14000385].  \n- Conduct structured goals-of-care discussion post-stabilization to clarify preferences regarding further systemic therapy versus best supportive care.  \n- Retrieve and review full primary pathology and any prior molecular testing; if absent, consider feasibility and value of new profiling.  \n- Obtain full 2025-04-09 CT report and any PET/CT to define metastatic burden, complications, and need for local palliative interventions.  \n- After data completion, re-convene MDT to weigh modest systemic options against toxicity, prioritizing symptom-led palliative/supportive care if performance status poor.", "oncologist": "- Urgently correct severe anemia and complete anemia work-up; reassess ECOG, symptoms, nutrition, comorbidities, and preferences before new therapy [@20250624|14501112].  \n\n- Obtain full CT 2025-04-09 report and confirm any PET/CT to define metastatic burden, complications, and trends (currently missing).  \n\n- Retrieve original pathology and any prior molecular testing; if absent, consider profiling to clarify histology and actionable biomarkers (all currently unknown).  \n\n- Reconstruct detailed prior systemic treatment history and responses to better infer platinum sensitivity and realistic benefit of further systemic therapy (missing).  \n\n- After stabilization and data completion, re-discuss at MDT and with patient/family to decide between limited further therapy versus best supportive care.", "radiologist": "- CT confirms metastatic ovarian cancer; exact metastatic sites, lesion sizes, and complications remain unspecified and require full report retrieval. [@IMAGING_STUDIES|2025-04-09]\n\n- Comparison of 2025-04-09 CT with any earlier imaging is undocumented; prior studies must be located to assess progression trend. [@IMAGING_TRENDS|2025-04-09]\n\n- Presence or absence of obstructive complications (bowel, ureteric, biliary) on CT is unknown; detailed abdominopelvic review is needed. [unknown/needs update]\n\n- PET/CT history and findings are undocumented; confirm if performed and upload reports/images to better define metabolic disease extent. [unknown/needs update]\n\n- Once complete imaging is available, provide structured staging, RECIST measurability, and description of any life-threatening complications for MDT planning. [unknown/needs update]", "pathologist": "- Original ovarian tumor histology, grade, staging, and IHC remain unknown/needs update; retrieve and upload full primary pathology report.  \n- Clarify whether any prior molecular testing (BRCA1/2, HRD, MSI, TMB, PD-L1, HER2) was done; currently unknown/needs update.  \n- Once pathology is available, confirm epithelial ovarian origin versus alternative primary and summarize key prognostic/pathologic features for MDT.  \n- If sufficient archived tissue exists, consider feasibility of additional biomarker testing, but only after full prior pathology/molecular review.  \n- Ensure all pathology and molecular documents are correctly labeled and dated to avoid misinterpretation in future MDT discussions.", "nuclear": "- No PET/CT or nuclear report is available; metabolic disease distribution and recurrence pattern remain unknown/needs update [@PET_CT|unknown].  \n- CT shows metastatic ovarian cancer, but organ involvement, lesion size, and complications remain insufficiently characterized/needs update [@IMAGING_CONTEXT|2025-04-09].  \n- Clarifying whether any prior PET/CT exists is critical to better define current metastatic spread and potential extra-abdominal disease.  \n- Once available, PET/CT could help distinguish active disease from treatment-related changes or benign findings on CT, refining staging.  \n- In this heavily pretreated, palliative setting, PET’s main role would be clarifying true progression versus equivocal CT findings, not surveillance."}}, "interaction_log": {"Round 1": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before proposing any further systemic therapy, please first stabilize anemia (including transfusion decision) and document ECOG, symptom burden, and goals of care; with this heavy pretreatment, we must be explicit whether additional drugs are realistically palliative versus shifting to best supportive care.", "radiologist": "Please provide the full 2025-04-09 CT report and any prior comparative imaging to clarify current disease burden, complications, and tempo, as this is critical for deciding whether further systemic therapy is appropriate.", "pathologist": "We need the original ovarian pathology report including histologic subtype, grade, and any prior biomarker testing to inform remaining systemic options versus supportive care only.", "nuclear": "At this stage, do you see any indication for further functional imaging, or would it only add burden without changing management, given heavy pretreatment and anemia?"}, "oncologist": {"chair": "Before deciding on any further systemic therapy versus best supportive care, we urgently need ECOG status, symptom burden, anemia work-up/transfusion history, and the full 2025-04-09 CT report including trends.", "oncologist": null, "radiologist": "We need the detailed 2025-04-09 CT report and comparison with prior imaging, highlighting disease extent, complications (e.g., bowel obstruction, hydronephrosis), and any rapid progression.", "pathologist": "Please confirm histologic subtype/grade for this ovarian cancer and whether any prior molecular testing (BRCA/HRD, MSI, HER2, others) was done and can be reported.", "nuclear": null}, "radiologist": {"chair": null, "oncologist": "Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications.", "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": "Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded.", "oncologist": "Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet.", "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": "No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern.", "radiologist": "Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.", "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": "Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient.", "radiologist": "The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.", "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}, "Round 2": {"Turn 1": {"chair": {"chair": null, "oncologist": "Before proposing further systemic therapy, please address and document anemia management (including transfusion decision), ECOG, symptom burden, nutrition, and explicit goals-of-care, as these are critical for safely deciding between additional treatment and best supportive care.", "radiologist": "Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions.", "pathologist": "Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown.", "nuclear": "If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records."}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}, "Turn 2": {"chair": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "oncologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "radiologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "pathologist": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}, "nuclear": {"chair": null, "oncologist": null, "radiologist": null, "pathologist": null, "nuclear": null}}}}, "agent_logs": {"chair": [{"role": "chair", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Heavily pretreated metastatic ovarian cancer with rising markers and anemia; current systemic regimen and performance status are unknown/need update.  \n- Prior extensive platinum, liposomal/standard anthracycline, anti-angiogenic, PARP, and immunotherapy exposure suggests limited further cytotoxic benefit; clarify platinum sensitivity.  \n- Immediate priority: correct severe anemia (Hgb 67 g/L) and assess symptoms, nutrition, renal/hepatic function, ECOG.  \n- Obtain histology subtype, BRCA1/2 and HRD status, and complete 2025 imaging reports to guide further systemic vs best supportive care.  \n- Discuss goals of care with patient/family now, aligning intensity of future treatment with prognosis and quality-of-life priorities.", "timestamp": "2026-01-17T20:09:35.647502"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before proposing any further systemic therapy, please first stabilize anemia (including transfusion decision) and document ECOG, symptom burden, and goals of care; with this heavy pretreatment, we must be explicit whether additional drugs are realistically palliative versus shifting to best supportive care.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Please provide the full 2025-04-09 CT report and any prior comparative imaging to clarify current disease burden, complications, and tempo, as this is critical for deciding whether further systemic therapy is appropriate.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"We need the original ovarian pathology report including histologic subtype, grade, and any prior biomarker testing to inform remaining systemic options versus supportive care only.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"At this stage, do you see any indication for further functional imaging, or would it only add burden without changing management, given heavy pretreatment and anemia?\",\"why\":\"safety\"}]}", "timestamp": "2026-01-17T20:09:59.055750"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:10:08.563983"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n[R1T2 DELTA] chair->oncologist(safety): Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient. | chair->radiologist(missing): The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Prioritize stabilization: evaluate anemia cause, consider transfusion, repeat CBC/biochem, document ECOG, symptoms, nutrition, comorbidities [@20250624|14501112; @20250624|14000385].  \n- Retrieve and review original pathology, including histologic subtype, grade, and any prior molecular testing; order germline/somatic profiling if absent.  \n- Obtain full 2025-04-09 CT report and any subsequent imaging; assess disease distribution, complications, and trend vs prior (currently unknown).  \n- Reconstruct detailed systemic treatment history (agents, dates, responses, toxicities, PFI) to clarify platinum status and realistic systemic options.  \n- After stabilization and data completion, hold MDT plus goals-of-care meeting to weigh further systemic therapy versus best supportive/palliative care.", "timestamp": "2026-01-17T20:10:16.922308"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Before proposing further systemic therapy, please address and document anemia management (including transfusion decision), ECOG, symptom burden, nutrition, and explicit goals-of-care, as these are critical for safely deciding between additional treatment and best supportive care.\",\"why\":\"safety\"},{\"target\":\"radiologist\",\"message\":\"Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown.\",\"why\":\"missing\"},{\"target\":\"nuclear\",\"message\":\"If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:11:01.070872"}, {"role": "chair", "user_message": "ROLE: chair. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nAllowed targets: [oncologist,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:13.118204"}, {"role": "chair", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Correct severe anemia urgently, including transfusion consideration; reassess ECOG, symptoms, nutrition, and organ function afterward [@20250624|14501112; @20250624|14000385].  \n- Conduct structured goals-of-care discussion post-stabilization to clarify preferences regarding further systemic therapy versus best supportive care.  \n- Retrieve and review full primary pathology and any prior molecular testing; if absent, consider feasibility and value of new profiling.  \n- Obtain full 2025-04-09 CT report and any PET/CT to define metastatic burden, complications, and need for local palliative interventions.  \n- After data completion, re-convene MDT to weigh modest systemic options against toxicity, prioritizing symptom-led palliative/supportive care if performance status poor.", "timestamp": "2026-01-17T20:11:53.657776"}, {"role": "chair", "user_message": "\nAs the MDT chair for gynecologic oncology, you are seeing the patient at OUTPATIENT TIME: 2025-06-27 15:54:59.567000.\nBased on PATIENT FACTS + MDT discussion + FINAL refined plans from all experts, determine the CURRENT best management plan for this visit.\n\nSTRICT RULES:\n- Any factual statement about past tests/treatments must include [@report_id|date] or say unknown.\n- If experts disagree, pick the safest plan and state the key uncertainty.\n\n# FINAL REFINED PLANS (All experts, last round)\n{\n  \"Round 1\": {\n    \"chair\": \"- Prioritize stabilization: evaluate anemia cause, consider transfusion, repeat CBC/biochem, document ECOG, symptoms, nutrition, comorbidities [@20250624|14501112; @20250624|14000385].  \\n- Retrieve and review original pathology, including histologic subtype, grade, and any prior molecular testing; order germline/somatic profiling if absent.  \\n- Obtain full 2025-04-09 CT report and any subsequent imaging; assess disease distribution, complications, and trend vs prior (currently unknown).  \\n- Reconstruct detailed systemic treatment history (agents, dates, responses, toxicities, PFI) to clarify platinum status and realistic systemic options.  \\n- After stabilization and data completion, hold MDT plus goals-of-care meeting to weigh further systemic therapy versus best supportive/palliative care.\",\n    \"oncologist\": \"- Correct severe anemia urgently (transfusion and work-up), then document ECOG, symptom burden, nutrition, and comorbidities before any new regimen [@20250624|14501112].  \\n\\n- Obtain and review full 2025-04-09 CT report (organs involved, complications, comparison) and any PET/CT to reassess disease burden (currently missing).  \\n\\n- Retrieve original pathology to confirm epithelial subtype/grade and review any prior molecular testing; if absent, consider comprehensive profiling (currently unknown).  \\n\\n- Reconstruct detailed prior systemic treatment history, including responses and toxicities, to clarify platinum sensitivity and realistic benefit of further therapy (missing).  \\n\\n- After stabilization and data completion, re-discuss at MDT and with patient/family to choose between limited further systemic therapy versus best supportive care.\",\n    \"radiologist\": \"- Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison) remains missing; must be retrieved/uploaded before MDT. [@IMAGING_STUDIES|2025-04-09]\\n\\n- PET/CT since 2025-04-09 is unknown; confirm if performed and obtain report/images to define metabolic burden and complications. [unknown/needs update]\\n\\n- Without full imaging, current disease extent, obstruction risk, or other complications cannot be adequately assessed for further systemic vs supportive care decisions. [@IMAGING_STUDIES|2025-04-09]\\n\\n- Once prior imaging is available, perform structured radiologic staging and measurability assessment to support objective response evaluation if therapy pursued. [unknown/needs update]\",\n    \"pathologist\": \"- Retrieve and review original ovarian cancer pathology: histologic subtype, grade, stage, and biomarker profile are completely unknown/needs update.  \\n- Obtain details of any prior molecular testing (BRCA1/2, HRD, MSI, TMB, PD-L1, HER2); currently unknown/needs update.  \\n- Confirm disease origin as ovarian versus alternative primary once pathology is available; present clarification at next MDT.  \\n- Once tissue and molecular data are complete, update pathology summary focusing on features relevant to further systemic options (no regimens suggested).  \\n- Ensure all key pathology and molecular reports are uploaded and correctly dated to avoid future discrepancies in MDT decisions.\",\n    \"nuclear\": \"- No PET/CT available; current metabolic disease distribution and recurrence pattern remain unknown/needs update [@PET_CT|unknown].  \\n- Full CT 2025-04-09 report is still missing; without it, we cannot correlate anatomic and potential metabolic burden [@IMAGING_CONTEXT|2025-04-09].  \\n- If PET/CT is performed, key goals: clarify extra-abdominal spread, occult nodal disease, and complications not fully characterized on CT.  \\n- PET would meaningfully change staging only if it reveals unsuspected distant metastases or non-malignant explanations for some CT lesions.  \\n- For suspected recurrence/progression, PET could reclassify equivocal CT findings, influencing decisions about local versus purely systemic/supportive approaches.\"\n  },\n  \"Round 2\": {\n    \"chair\": \"- Correct severe anemia urgently, including transfusion consideration; reassess ECOG, symptoms, nutrition, and organ function afterward [@20250624|14501112; @20250624|14000385].  \\n- Conduct structured goals-of-care discussion post-stabilization to clarify preferences regarding further systemic therapy versus best supportive care.  \\n- Retrieve and review full primary pathology and any prior molecular testing; if absent, consider feasibility and value of new profiling.  \\n- Obtain full 2025-04-09 CT report and any PET/CT to define metastatic burden, complications, and need for local palliative interventions.  \\n- After data completion, re-convene MDT to weigh modest systemic options against toxicity, prioritizing symptom-led palliative/supportive care if performance status poor.\",\n    \"oncologist\": \"- Urgently correct severe anemia and complete anemia work-up; reassess ECOG, symptoms, nutrition, comorbidities, and preferences before new therapy [@20250624|14501112].  \\n\\n- Obtain full CT 2025-04-09 report and confirm any PET/CT to define metastatic burden, complications, and trends (currently missing).  \\n\\n- Retrieve original pathology and any prior molecular testing; if absent, consider profiling to clarify histology and actionable biomarkers (all currently unknown).  \\n\\n- Reconstruct detailed prior systemic treatment history and responses to better infer platinum sensitivity and realistic benefit of further systemic therapy (missing).  \\n\\n- After stabilization and data completion, re-discuss at MDT and with patient/family to decide between limited further therapy versus best supportive care.\",\n    \"radiologist\": \"- CT confirms metastatic ovarian cancer; exact metastatic sites, lesion sizes, and complications remain unspecified and require full report retrieval. [@IMAGING_STUDIES|2025-04-09]\\n\\n- Comparison of 2025-04-09 CT with any earlier imaging is undocumented; prior studies must be located to assess progression trend. [@IMAGING_TRENDS|2025-04-09]\\n\\n- Presence or absence of obstructive complications (bowel, ureteric, biliary) on CT is unknown; detailed abdominopelvic review is needed. [unknown/needs update]\\n\\n- PET/CT history and findings are undocumented; confirm if performed and upload reports/images to better define metabolic disease extent. [unknown/needs update]\\n\\n- Once complete imaging is available, provide structured staging, RECIST measurability, and description of any life-threatening complications for MDT planning. [unknown/needs update]\",\n    \"pathologist\": \"- Original ovarian tumor histology, grade, staging, and IHC remain unknown/needs update; retrieve and upload full primary pathology report.  \\n- Clarify whether any prior molecular testing (BRCA1/2, HRD, MSI, TMB, PD-L1, HER2) was done; currently unknown/needs update.  \\n- Once pathology is available, confirm epithelial ovarian origin versus alternative primary and summarize key prognostic/pathologic features for MDT.  \\n- If sufficient archived tissue exists, consider feasibility of additional biomarker testing, but only after full prior pathology/molecular review.  \\n- Ensure all pathology and molecular documents are correctly labeled and dated to avoid misinterpretation in future MDT discussions.\",\n    \"nuclear\": \"- No PET/CT or nuclear report is available; metabolic disease distribution and recurrence pattern remain unknown/needs update [@PET_CT|unknown].  \\n- CT shows metastatic ovarian cancer, but organ involvement, lesion size, and complications remain insufficiently characterized/needs update [@IMAGING_CONTEXT|2025-04-09].  \\n- Clarifying whether any prior PET/CT exists is critical to better define current metastatic spread and potential extra-abdominal disease.  \\n- Once available, PET/CT could help distinguish active disease from treatment-related changes or benign findings on CT, refining staging.  \\n- In this heavily pretreated, palliative setting, PET’s main role would be clarifying true progression versus equivocal CT findings, not surveillance.\"\n  }\n}\n\n# Response Format\nFinal Assessment:\n<1–3 sentences: summarize histology/biology, current disease status, and key uncertainties>\n\nCore Treatment Strategy:\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n- < ≤20 words concrete decision >\n\nChange Triggers:\n- < ≤20 words “if X, then adjust management from A to B” >\n- < ≤20 words “if X, then adjust management from A to B” >\n", "assistant_reply": "Final Assessment:\nHeavily pretreated recurrent metastatic ovarian cancer with severe anemia and incomplete pathology/imaging/biomarker data; prognosis guarded and decisions must follow stabilization and clarified goals.\n\nCore Treatment Strategy:\n- Urgently correct severe anemia and optimize nutrition/organ function before any further anti-tumor treatment [@20250624|14501112; @20250624|14000385].  \n- After stabilization, reassess ECOG, symptoms, and patient preferences; prioritize symptom-led palliative/supportive care if performance status poor.  \n- Retrieve full primary pathology and any prior molecular reports; if absent, evaluate feasibility/value of new profiling (including BRCA/HRD).  \n- Obtain complete 2025-04-09 CT report (±PET/CT if justified) to define burden/complications and identify candidates for local palliation.  \n\nChange Triggers:\n- If performance status remains ≥3 or patient declines further therapy, shift fully to best supportive and hospice-oriented care.  \n- If performance status ≤2 and patient desires treatment, reconsider limited systemic options versus focused local interventions at repeat MDT review.", "timestamp": "2026-01-17T20:12:16.934132"}], "oncologist": [{"role": "oncologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Heavily pretreated metastatic ovarian cancer with progression after multiple cytotoxic, anti-angiogenic, oral targeted, and immunotherapy regimens; palliative intent.  \n\n- Current disease progression: multiple metastases on CT 2025-04-09 with markedly rising CA125/HE4/CA15-3 [@20250625|13601595].  \n\n- Profound anemia (Hb 67 g/L) with preserved liver enzymes and creatinine; requires cause assessment and correction before further systemic therapy [@20250624|14501112][@20250624|14000385].  \n\n- No germline/somatic mutations, MSI, TMB, or PD-L1 data available; comprehensive molecular profiling status and reports need updating.  \n\n- Missing details: exact histology/grade, staging, performance status, organ function (full labs), prior regimen toxicities, prior response durations, and sites/symptoms.", "timestamp": "2026-01-17T20:09:38.272198"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"chair\",\"message\":\"Before deciding on any further systemic therapy versus best supportive care, we urgently need ECOG status, symptom burden, anemia work-up/transfusion history, and the full 2025-04-09 CT report including trends.\",\"why\":\"missing\"},{\"target\":\"pathologist\",\"message\":\"Please confirm histologic subtype/grade for this ovarian cancer and whether any prior molecular testing (BRCA/HRD, MSI, HER2, others) was done and can be reported.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"We need the detailed 2025-04-09 CT report and comparison with prior imaging, highlighting disease extent, complications (e.g., bowel obstruction, hydronephrosis), and any rapid progression.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:10:01.481943"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:10:09.778589"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n[R1T2 DELTA] chair->oncologist(safety): Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient. | chair->radiologist(missing): The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Correct severe anemia urgently (transfusion and work-up), then document ECOG, symptom burden, nutrition, and comorbidities before any new regimen [@20250624|14501112].  \n\n- Obtain and review full 2025-04-09 CT report (organs involved, complications, comparison) and any PET/CT to reassess disease burden (currently missing).  \n\n- Retrieve original pathology to confirm epithelial subtype/grade and review any prior molecular testing; if absent, consider comprehensive profiling (currently unknown).  \n\n- Reconstruct detailed prior systemic treatment history, including responses and toxicities, to clarify platinum sensitivity and realistic benefit of further therapy (missing).  \n\n- After stabilization and data completion, re-discuss at MDT and with patient/family to choose between limited further systemic therapy versus best supportive care.", "timestamp": "2026-01-17T20:10:19.795820"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:03.113520"}, {"role": "oncologist", "user_message": "ROLE: oncologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nAllowed targets: [chair,radiologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:18.201133"}, {"role": "oncologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Urgently correct severe anemia and complete anemia work-up; reassess ECOG, symptoms, nutrition, comorbidities, and preferences before new therapy [@20250624|14501112].  \n\n- Obtain full CT 2025-04-09 report and confirm any PET/CT to define metastatic burden, complications, and trends (currently missing).  \n\n- Retrieve original pathology and any prior molecular testing; if absent, consider profiling to clarify histology and actionable biomarkers (all currently unknown).  \n\n- Reconstruct detailed prior systemic treatment history and responses to better infer platinum sensitivity and realistic benefit of further systemic therapy (missing).  \n\n- After stabilization and data completion, re-discuss at MDT and with patient/family to decide between limited further therapy versus best supportive care.", "timestamp": "2026-01-17T20:12:01.539056"}], "radiologist": [{"role": "radiologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- CT shows ovarian malignancy with multiple metastatic sites; precise organs, sizes, and counts not specified and need updated imaging report. [@IMAGING_STUDIES|2025-04-09]\n\n- Overall metastatic burden and distribution trend versus any earlier baseline are unknown; prior comparison imaging, if available, needs review. [@IMAGING_TRENDS|2025-04-09]\n\n- No documentation of complications such as obstruction, ascites, or organ compromise; targeted CT/PET report needed to assess. [unknown/needs update]\n\n- Lesion measurability for response assessment (target vs non-target lesions) cannot be determined; require full radiology report with measurements. [unknown/needs update]", "timestamp": "2026-01-17T20:09:40.469792"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:10:03.027138"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:10:10.967979"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n[R1T2 DELTA] chair->oncologist(safety): Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient. | chair->radiologist(missing): The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison) remains missing; must be retrieved/uploaded before MDT. [@IMAGING_STUDIES|2025-04-09]\n\n- PET/CT since 2025-04-09 is unknown; confirm if performed and obtain report/images to define metabolic burden and complications. [unknown/needs update]\n\n- Without full imaging, current disease extent, obstruction risk, or other complications cannot be adequately assessed for further systemic vs supportive care decisions. [@IMAGING_STUDIES|2025-04-09]\n\n- Once prior imaging is available, perform structured radiologic staging and measurability assessment to support objective response evaluation if therapy pursued. [unknown/needs update]", "timestamp": "2026-01-17T20:10:24.124382"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:08.282103"}, {"role": "radiologist", "user_message": "ROLE: radiologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nAllowed targets: [chair,oncologist,pathologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:19.871262"}, {"role": "radiologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- CT confirms metastatic ovarian cancer; exact metastatic sites, lesion sizes, and complications remain unspecified and require full report retrieval. [@IMAGING_STUDIES|2025-04-09]\n\n- Comparison of 2025-04-09 CT with any earlier imaging is undocumented; prior studies must be located to assess progression trend. [@IMAGING_TRENDS|2025-04-09]\n\n- Presence or absence of obstructive complications (bowel, ureteric, biliary) on CT is unknown; detailed abdominopelvic review is needed. [unknown/needs update]\n\n- PET/CT history and findings are undocumented; confirm if performed and upload reports/images to better define metabolic disease extent. [unknown/needs update]\n\n- Once complete imaging is available, provide structured staging, RECIST measurability, and description of any life-threatening complications for MDT planning. [unknown/needs update]", "timestamp": "2026-01-17T20:12:04.330318"}], "pathologist": [{"role": "pathologist", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- Markedly elevated CA125 and HE4 with high ROMA suggest strong suspicion for epithelial ovarian malignancy; histologic confirmation absent. [@MOLECULAR|unknown]  \n- Normal AFP, CEA, CA19-9, CA15-3 reduce support for primary germ cell or GI-type tumor markers. [@MOLECULAR|unknown]  \n- No tissue diagnosis, histologic type, or grade available; surgical pathology or biopsy report urgently needed. [@PATHOLOGY_REPORTS|unknown]  \n- HER2, MSI, PD-L1 CPS, and TMB all unknown; these biomarkers require dedicated testing if clinically indicated. [@MOLECULAR|unknown]  \n- Germline and somatic mutation panels show no reported variants; confirm panel type, genes covered, and report date. [@MOLECULAR|unknown]", "timestamp": "2026-01-17T20:09:42.901283"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet.\",\"why\":\"missing\"},{\"target\":\"chair\",\"message\":\"Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:10:04.667277"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:10:12.911721"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n[R1T2 DELTA] chair->oncologist(safety): Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient. | chair->radiologist(missing): The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Retrieve and review original ovarian cancer pathology: histologic subtype, grade, stage, and biomarker profile are completely unknown/needs update.  \n- Obtain details of any prior molecular testing (BRCA1/2, HRD, MSI, TMB, PD-L1, HER2); currently unknown/needs update.  \n- Confirm disease origin as ovarian versus alternative primary once pathology is available; present clarification at next MDT.  \n- Once tissue and molecular data are complete, update pathology summary focusing on features relevant to further systemic options (no regimens suggested).  \n- Ensure all key pathology and molecular reports are uploaded and correctly dated to avoid future discrepancies in MDT decisions.", "timestamp": "2026-01-17T20:10:44.483995"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:09.860748"}, {"role": "pathologist", "user_message": "ROLE: pathologist. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nAllowed targets: [chair,oncologist,radiologist,nuclear]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:24.761354"}, {"role": "pathologist", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- Original ovarian tumor histology, grade, staging, and IHC remain unknown/needs update; retrieve and upload full primary pathology report.  \n- Clarify whether any prior molecular testing (BRCA1/2, HRD, MSI, TMB, PD-L1, HER2) was done; currently unknown/needs update.  \n- Once pathology is available, confirm epithelial ovarian origin versus alternative primary and summarize key prognostic/pathologic features for MDT.  \n- If sufficient archived tissue exists, consider feasibility of additional biomarker testing, but only after full prior pathology/molecular review.  \n- Ensure all pathology and molecular documents are correctly labeled and dated to avoid misinterpretation in future MDT discussions.", "timestamp": "2026-01-17T20:12:11.323081"}], "nuclear": [{"role": "nuclear", "user_message": "Give INITIAL opinion (use ONLY your system-provided patient facts).\nReturn up to 5 bullets, each ≤20 words.\nIf key data missing, say exactly what needs updating.", "assistant_reply": "- No PET/CT report available; current staging metabolic extent is unknown/needs update [@PET_CT|unknown].  \n- Prior imaging shows ovarian cancer with multiple metastases, but metabolic activity pattern is unknown/needs update [@IMAGING_CONTEXT|2025-04-09].  \n- Cannot assess PET impact on upstaging/downstaging or recurrence suspicion without a current PET report; acquisition status unknown/needs update.  \n- Need PET/CT date, acquisition protocol, FDG-avid lesion distribution, and SUV metrics to refine metastatic burden assessment.  \n- Request upload/verification of latest PET/CT report to determine any change in staging or recurrence suspicion.", "timestamp": "2026-01-17T20:09:44.920804"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"yes\",\"messages\":[{\"target\":\"oncologist\",\"message\":\"No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern.\",\"why\":\"missing\"},{\"target\":\"radiologist\",\"message\":\"Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\",\"why\":\"missing\"}]}", "timestamp": "2026-01-17T20:10:06.441157"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:10:14.226598"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n[R1T2 DELTA] chair->oncologist(safety): Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient. | chair->radiologist(missing): The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- No PET/CT available; current metabolic disease distribution and recurrence pattern remain unknown/needs update [@PET_CT|unknown].  \n- Full CT 2025-04-09 report is still missing; without it, we cannot correlate anatomic and potential metabolic burden [@IMAGING_CONTEXT|2025-04-09].  \n- If PET/CT is performed, key goals: clarify extra-abdominal spread, occult nodal disease, and complications not fully characterized on CT.  \n- PET would meaningfully change staging only if it reveals unsuspected distant metastases or non-malignant explanations for some CT lesions.  \n- For suspected recurrence/progression, PET could reclassify equivocal CT findings, influencing decisions about local versus purely systemic/supportive approaches.", "timestamp": "2026-01-17T20:10:47.233161"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:11.262619"}, {"role": "nuclear", "user_message": "ROLE: nuclear. VISIT: 2025-06-27 15:54:59.567000\nDefault is NOT to speak. Speak ONLY if: conflict | safety | missing-critical | new-critical.\n\nCONTEXT (latest):\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nAllowed targets: [chair,oncologist,radiologist,pathologist]\nReturn ONE-LINE JSON only:{\"speak\":\"yes/no\",\"messages\":[{\"target\":\"<role>\",\"message\":\"<1-2 sentences>\",\"why\":\"conflict|safety|missing|new\"}]}", "assistant_reply": "{\"speak\":\"no\",\"messages\":[]}", "timestamp": "2026-01-17T20:11:51.039116"}, {"role": "nuclear", "user_message": "Given MDT context:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.\n[R2T1 DELTA] of-care, as these are critical for safely deciding between additional treatment and best supportive care. | chair->radiologist(missing): Kindly obtain and upload the full 2025-04-09 CT report (sites, measurements, complications, comparison) and confirm whether any PET/CT exists, as current imaging detail is insufficient to guide further management decisions. | chair->pathologist(missing): Please retrieve and upload the original ovarian tumor pathology, including histologic subtype/grade and any immunohistochemistry, and indicate whether prior molecular testing was performed, as current histology and biomarker status are unknown. | chair->nuclear(missing): If any prior PET/CT or relevant nuclear study has been performed externally, please help confirm and obtain the reports/images, since metastatic distribution and potential complications are incompletely characterized on current records.\n\nProvide FINAL refined plan.\nUp to 5 bullets, each ≤20 words.\nAny factual claim must include [@report_id|date] or say unknown.", "assistant_reply": "- No PET/CT or nuclear report is available; metabolic disease distribution and recurrence pattern remain unknown/needs update [@PET_CT|unknown].  \n- CT shows metastatic ovarian cancer, but organ involvement, lesion size, and complications remain insufficiently characterized/needs update [@IMAGING_CONTEXT|2025-04-09].  \n- Clarifying whether any prior PET/CT exists is critical to better define current metastatic spread and potential extra-abdominal disease.  \n- Once available, PET/CT could help distinguish active disease from treatment-related changes or benign findings on CT, refining staging.  \n- In this heavily pretreated, palliative setting, PET’s main role would be clarifying true progression versus equivocal CT findings, not surveillance.", "timestamp": "2026-01-17T20:12:13.807257"}], "assistant": [{"role": "assistant", "user_message": "Summarize expert opinions concisely for MDT.\n{\"chair\":\"- Heavily pretreated metastatic ovarian cancer with rising markers and anemia; current systemic regimen and performance status are unknown/need update.  \\n- Prior extensive platinum, liposomal/standard anthracycline, anti-angiogenic, PARP, and immunotherapy exposure suggests limited further cytotoxic benefit; clarify platinum sensitivity.  \\n- Immediate priority: correct severe anemia (Hgb 67 g/L) and assess symptoms, nutrition, renal/hepatic function, ECOG.  \\n- Obtain histology subtype, BRCA1/2 and HRD status, and complete 2025 imaging reports to guide further systemic vs best supportive care.  \\n- Discuss goals of care with patient/family now, aligning intensity of future treatment with prognosis and quality-of-life priorities.\",\"oncologist\":\"- Heavily pretreated metastatic ovarian cancer with progression after multiple cytotoxic, anti-angiogenic, oral targeted, and immunotherapy regimens; palliative intent.  \\n\\n- Current disease progression: multiple metastases on CT 2025-04-09 with markedly rising CA125/HE4/CA15-3 [@20250625|13601595].  \\n\\n- Profound anemia (Hb 67 g/L) with preserved liver enzymes and creatinine; requires cause assessment and correction before further systemic therapy [@20250624|14501112][@20250624|14000385].  \\n\\n- No germline/somatic mutations, MSI, TMB, or PD-L1 data available; comprehensive molecular profiling status and reports need updating.  \\n\\n- Missing details: exact histology/grade, staging, performance status, organ function (full labs), prior regimen toxicities, prior response durations, and sites/symptoms.\",\"radiologist\":\"- CT shows ovarian malignancy with multiple metastatic sites; precise organs, sizes, and counts not specified and need updated imaging report. [@IMAGING_STUDIES|2025-04-09]\\n\\n- Overall metastatic burden and distribution trend versus any earlier baseline are unknown; prior comparison imaging, if available, needs review. [@IMAGING_TRENDS|2025-04-09]\\n\\n- No documentation of complications such as obstruction, ascites, or organ compromise; targeted CT/PET report needed to assess. [unknown/needs update]\\n\\n- Lesion measurability for response assessment (target vs non-target lesions) cannot be determined; require full radiology report with measurements. [unknown/needs update]\",\"pathologist\":\"- Markedly elevated CA125 and HE4 with high ROMA suggest strong suspicion for epithelial ovarian malignancy; histologic confirmation absent. [@MOLECULAR|unknown]  \\n- Normal AFP, CEA, CA19-9, CA15-3 reduce support for primary germ cell or GI-type tumor markers. [@MOLECULAR|unknown]  \\n- No tissue diagnosis, histologic type, or grade available; surgical pathology or biopsy report urgently needed. [@PATHOLOGY_REPORTS|unknown]  \\n- HER2, MSI, PD-L1 CPS, and TMB all unknown; these biomarkers require dedicated testing if clinically indicated. [@MOLECULAR|unknown]  \\n- Germline and somatic mutation panels show no reported variants; confirm panel type, genes covered, and report date. [@MOLECULAR|unknown]\",\"nuclear\":\"- No PET/CT report available; current staging metabolic extent is unknown/needs update [@PET_CT|unknown].  \\n- Prior imaging shows ovarian cancer with multiple metastases, but metabolic activity pattern is unknown/needs update [@IMAGING_CONTEXT|2025-04-09].  \\n- Cannot assess PET impact on upstaging/downstaging or recurrence suspicion without a current PET report; acquisition status unknown/needs update.  \\n- Need PET/CT date, acquisition protocol, FDG-avid lesion distribution, and SUV metrics to refine metastatic burden assessment.  \\n- Request upload/verification of latest PET/CT report to determine any change in staging or recurrence suspicion.\"}\n\nOutput:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Heavily pretreated metastatic ovarian cancer, palliative intent; multiple prior lines including platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.  \n- Current progression with multiple metastases on CT (09-04-2025) and markedly rising CA125/HE4/CA15-3.  \n- Profound anemia (Hb 67 g/L) with currently preserved creatinine and liver enzymes; symptom burden, nutrition, and ECOG not documented.  \n- Tumor markers (CA125/HE4, ROMA) strongly support epithelial ovarian origin; other tumor markers (AFP, CEA, CA19-9, CA15-3) not suggestive of alternate primary.  \n\nControversies:\n- Unclear whether further systemic therapy offers meaningful benefit versus best supportive care in the context of heavy pretreatment and unknown performance status.  \n- Platinum sensitivity status not defined, impacting consideration of any further platinum-based therapy.  \n\nMissing Info:\n- Clinical: ECOG performance status, symptom profile (pain, ascites, obstruction, bleeding), nutritional status, detailed comorbidities, transfusion history, and anemia work-up.  \n- Pathology: Confirmed histology subtype and grade, full surgical/biopsy pathology report.  \n- Molecular: BRCA1/2 and HRD status, MSI, TMB, PD-L1, HER2, details of any prior germline/somatic panels (genes, dates, results).  \n- Treatment history: Full list of systemic regimens, dates, doses, toxicities, and response durations.  \n- Imaging: Complete CT report (09-04-2025) with lesion sites, sizes, complications (ascites, obstruction, organ compromise), and previous imaging for trend; PET/CT report including FDG distribution and SUV if available.  \n- Organ function: Full recent labs (CBC with indices, iron studies, hemolysis panel, LFTs, renal function, coagulation).  \n- Goals of care: Documented discussion with patient/family regarding prognosis, preferences, and acceptable treatment burden.  \n\nWorking Plan:\n- Stabilize: Urgently assess and correct anemia; evaluate symptoms, nutritional status, and full organ function.  \n- Clarify disease and options: Obtain full pathology and molecular profile; retrieve and review complete CT and any PET/CT reports; reconstruct full prior treatment and response history, including platinum sensitivity.  \n- Multidisciplinary review: Re-discuss at MDT once above data are available to outline realistic systemic options (if any) versus best supportive/palliative care.  \n- Communication: Initiate/continue goals-of-care discussion with patient and family to align future management intensity with prognosis and quality-of-life priorities.", "timestamp": "2026-01-17T20:09:50.392707"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Heavily pretreated metastatic ovarian cancer, palliative intent; multiple prior lines including platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.  \n- Current progression with multiple metastases on CT (09-04-2025) and markedly rising CA125/HE4/CA15-3.  \n- Profound anemia (Hb 67 g/L) with currently preserved creatinine and liver enzymes; symptom burden, nutrition, and ECOG not documented.  \n- Tumor markers (CA125/HE4, ROMA) strongly support epithelial ovarian origin; other tumor markers (AFP, CEA, CA19-9, CA15-3) not suggestive of alternate primary.  \n\nControversies:\n- Unclear whether further systemic therapy offers meaningful benefit versus best supportive care in the context of heavy pretreatment and unknown performance status.  \n- Platinum sensitivity status not defined, impacting consideration of any further platinum-based therapy.  \n\nMissing Info:\n- Clinical: ECOG performance status, symptom profile (pain, ascites, obstruction, bleeding), nutritional status, detailed comorbidities, transfusion history, and anemia work-up.  \n- Pathology: Confirmed histology subtype and grade, full surgical/biopsy pathology report.  \n- Molecular: BRCA1/2 and HRD status, MSI, TMB, PD-L1, HER2, details of any prior germline/somatic panels (genes, dates, results).  \n- Treatment history: Full list of systemic regimens, dates, doses, toxicities, and response durations.  \n- Imaging: Complete CT report (09-04-2025) with lesion sites, sizes, complications (ascites, obstruction, organ compromise), and previous imaging for trend; PET/CT report including FDG distribution and SUV if available.  \n- Organ function: Full recent labs (CBC with indices, iron studies, hemolysis panel, LFTs, renal function, coagulation).  \n- Goals of care: Documented discussion with patient/family regarding prognosis, preferences, and acceptable treatment burden.  \n\nWorking Plan:\n- Stabilize: Urgently assess and correct anemia; evaluate symptoms, nutritional status, and full organ function.  \n- Clarify disease and options: Obtain full pathology and molecular profile; retrieve and review complete CT and any PET/CT reports; reconstruct full prior treatment and response history, including platinum sensitivity.  \n- Multidisciplinary review: Re-discuss at MDT once above data are available to outline realistic systemic options (if any) versus best supportive/palliative care.  \n- Communication: Initiate/continue goals-of-care discussion with patient and family to align future management intensity with prognosis and quality-of-life priorities.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.", "timestamp": "2026-01-17T20:09:54.610762"}, {"role": "assistant", "user_message": "MDT global knowledge:\nKey Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer, palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, immunotherapy.\n- Radiologic and marker progression (CT 09-04-2025; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; performance status and symptom burden unknown.\n\nControversies:\n- Whether any further systemic therapy is meaningful versus best supportive care, given heavy pretreatment and unknown ECOG.\n- Platinum sensitivity status unclear, limiting planning of any further platinum use.\n\nMissing Info:\n- Clinical: ECOG, detailed symptoms, nutrition, comorbidities, anemia work-up, transfusion history.\n- Pathology: Histologic subtype and grade, full pathology report.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2; details of any prior panels.\n- Treatment history: Complete regimen list with dates, toxicities, and response durations.\n- Imaging: Full CT (09-04-2025) report with trends; any PET/CT findings.\n- Labs: Comprehensive recent blood work.\n- Goals of care: Documented discussion of prognosis and treatment preferences.\n\nWorking Plan:\n- Stabilize anemia and assess full clinical status (ECOG, symptoms, nutrition, organ function).\n- Complete pathology and molecular characterization; reconstruct detailed treatment history and platinum sensitivity.\n- Obtain and review full imaging (CT ± PET/CT) for disease burden and complications.\n- Re-discuss at MDT with updated data to frame realistic options versus best supportive care.\n- Conduct/continue structured goals-of-care conversation with patient and family.\n[R1T1 DELTA] (missing): Full CT report from 2025-04-09 (organs involved, lesion measurements, complications, comparison to prior) is missing and essential for assessing current disease burden and potential complications. | pathologist->oncologist(missing): Histologic subtype, grade, and original pathology report are completely missing; I cannot confirm epithelial ovarian origin or biomarkers yet. | pathologist->chair(missing): Before further systemic decisions, we need the primary pathology report and any prior molecular panel results retrieved and uploaded. | nuclear->oncologist(missing): No PET/CT is available in the record; if performed, the report/images are needed to clarify current metabolic disease burden and potential recurrence pattern. | nuclear->radiologist(missing): Please confirm whether any PET/CT has been done since the 09-04-2025 CT and, if so, upload the full report and key findings.\n[R1T2 DELTA] chair->oncologist(safety): Before proposing any new systemic regimen, please urgently stabilize anemia (including transfusion decision) and document ECOG, symptoms, and goals of care, as proceeding without this risks disproportionate toxicity in a heavily pretreated patient. | chair->radiologist(missing): The full 2025-04-09 CT report (organs involved, complications, and comparison) is still missing; this is essential to judge whether further systemic therapy versus purely supportive care is appropriate.\n\nRe-summarize concisely. Must include:\nKey Knowledge:\n- ...\nControversies:\n- ...\nMissing Info:\n- ...\nWorking Plan:\n- ...", "assistant_reply": "Key Knowledge:\n- Heavily pretreated metastatic epithelial ovarian cancer under palliative intent; prior platinum, anthracycline, anti-angiogenic, PARP inhibitor, and immunotherapy.\n- Radiologic and marker progression (CT 2025-04-09; rising CA125/HE4/CA15-3).\n- Profound anemia (Hb 67 g/L) with preserved renal/liver function; ECOG and symptom burden not documented.\n\nControversies:\n- Clinical value of any further systemic therapy versus best supportive care in a heavily pretreated setting with unknown performance status.\n- Platinum sensitivity remains undefined, limiting consideration of further platinum-based treatment.\n\nMissing Info:\n- Clinical: ECOG, detailed symptom profile, nutrition, comorbidities, anemia work-up and transfusion history, explicit goals-of-care documentation.\n- Pathology: Original pathology report, histologic subtype and grade, confirmation of epithelial ovarian origin; prior molecular panel reports.\n- Molecular: BRCA1/2, HRD, MSI, TMB, PD-L1, HER2, and details of any previous germline/somatic testing.\n- Treatment history: Full regimen list with dates, dose intensity, toxicities, and response durations.\n- Imaging: Full CT 2025-04-09 report (organs involved, lesion measurements, complications, comparison to prior); confirmation and upload of any PET/CT and findings.\n- Labs: Comprehensive recent bloods (CBC with indices, iron/hemolysis work-up, LFTs, renal, coagulation).\n\nWorking Plan:\n- Immediate: Stabilize anemia (including transfusion decision) and document ECOG, symptoms, nutrition, and organ function; initiate/clarify goals-of-care discussion.\n- Diagnostics: Retrieve and upload full primary pathology and any molecular reports; obtain complete CT 2025-04-09 report and confirm any PET/CT; reconstruct full prior systemic treatment history and platinum sensitivity.\n- MDT: Re-discuss once the above data are available to define realistic systemic options (if any) versus best supportive/palliative care, guided by updated clinical status and patient preferences.", "timestamp": "2026-01-17T20:10:52.081039"}]}, "trace_events": [{"ts": "2026-01-17T20:08:58.975306", "event": "pipeline_start", "payload": {"visit_time": "2025-06-27 15:54:59.567000", "meta_info": "362201196403235065"}}, {"ts": "2026-01-17T20:08:58.975549", "event": "case_fingerprint", "payload": {"case_fingerprint": "d9b11a1ab0f2"}}, {"ts": "2026-01-17T20:08:59.231136", "event": "reports_loaded", "payload": {"lab_n": 16, "img_n": 2, "path_n": 0, "mut_n": 0, "cutoff_dt": "2025-06-28 15:54:59"}}, {"ts": "2026-01-17T20:09:09.632085", "event": "reports_selected", "payload": {"lab": {"chair": ["20250624|14000385|2025-06-24", "20250624|14501112|2025-06-24", "20250625|13601595|2025-06-25"], "oncologist": ["20250624|14000385|2025-06-24", "20250624|14501112|2025-06-24", "20250625|13601595|2025-06-25"], "radiologist": [], "pathologist": [], "nuclear": []}, "imaging": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "pathology": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}, "mutation": {"chair": [], "oncologist": [], "radiologist": [], "pathologist": [], "nuclear": []}}}, {"ts": "2026-01-17T20:09:30.216977", "event": "rag_query", "payload": {"query": "Heavily pretreated recurrent ovarian cancer, platinum status unclear, with multiple metastases on CT; no BRCA/HRD/MSI/PD-L1 data; significant anemia (Hgb 67), low albumin, rising CA125/HE4—guidance on systemic options and supportive care?"}}, {"ts": "2026-01-17T20:09:30.216981", "event": "rag_hits", "payload": {"topk": 5, "n": 0}}, {"ts": "2026-01-17T20:09:32.499992", "event": "mdt_discussion_start", "payload": {"num_rounds": 2, "num_turns": 2}}, {"ts": "2026-01-17T20:12:13.807415", "event": "mdt_discussion_end", "payload": {"merged_chars": 2924}}, {"ts": "2026-01-17T20:12:13.808337", "event": "final_output_start", "payload": {}}, {"ts": "2026-01-17T20:12:16.934295", "event": "final_output_end", "payload": {"final_output_chars": 1141}}], "trace_mermaid": "flowchart TD\n  A[Load Case + Fingerprint] --> B[Load Reports]\n  B --> C[Report Selection per Role]\n  C --> D[Global Guideline RAG]\n  D --> E[Init Specialist Agents]\n  E --> F[MDT Discussion Engine]\n  F --> G[Trial Matching]\n  G --> H[Final Chair Output]\n  H --> I[Save Logs]\n"}
